КАК ПРЕОДОЛЕТЬ ПОСЛЕДСТВИЯ ГИПЕРГЛИКЕМИЧЕСКОЙ ПАМЯТИ?


Цитировать

Полный текст

Аннотация

Рассматриваются вопросы патогенетической терапии диабетической полиневропатии. Обсуждаются фармакологические характеристики тиамина и его жирорастворимого аналога бенфотиамина. Особое внимание уделяется механизмам действия бенфотиамина с позиции гипергликемической памяти. Приводятся результаты клинических исследований эффективности и безопасности бенфотиамина. На примере препаратов Мильгамма композитум (бенфотиамин + пиридоксин) и Мильгамма (В1, В6 и В12) показана высокая клиническая эффективность комбинации витаминов группы В; обсуждаются вопросы их применения пациентами с сахарным диабетом в зависимости от течения дистальной полиневропатии.

Об авторах

Елена Валерьевна Бирюкова

МГМСУ

доктор медицинских наук, профессор кафедры эндокринологии Московского государственного медико-стоматологического университета; МГМСУ

Ye V Biryukova

Список литературы

  1. Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetic neuropathy. A statement by the American Diabetes Association. Diabetes Care 2005;28:956-62.
  2. Kempler P. Neuropathies. Pathomechanism, clinical presentation, diagnosis, therapy. Budapest: Springer Scientific Publisher, 2002.
  3. Said G. Diabetic Neuropathy. A Review. Nat Clin Pract Neurol 2007;3(6):331-40.
  4. DCCT: The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
  5. Ihnat MA, Thorpe JE, Ceriello A. The "metabolic memory", the new challenge of diabetes. Diabet Med 2007;24:582-86.
  6. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005;54:1615-25.
  7. Russell JW, Feldman EL. Impaired glucose tolerance - does it cause neuropathy? Muscle Nerve 2001;24:1109-12.
  8. Herman WH, Kennedy L. for the GOAL A1c study. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care 2005;28:1480-81.
  9. Happich M, John J, Stamenitis S, Clouth J, Polnau D. The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002 - results from the Diabetic Microvascular Complications (DIMICO) study. Diabetes Res Clin Pract 2008;81:223-30.
  10. Boulton AJM, Vileikyte L, Ragnarson-Tennwall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005a; 366: 1719-24.
  11. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care 2008;31:255-61.
  12. EDIC: The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensivetherapy on microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002;287:2563-69.
  13. Marshall S, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. Brit Med J 2006;333:475-80.
  14. Tesfaye S, Stevens LK, Stephenson JM, et al. for the EURODIAB IDDM Study Group. Prevalence of diabetic peripheral neuropathy and its relation to glycemic control and potential risk factors: the EURODIAB IDDM complications study. Diabetologia 1996;39:1377-84.
  15. Mooney S, Leuendorf J-E, Hendrickson C, Hellmann H. Vitaminus thiamine derivatives after oral administration. Int J Clin Pharmacol Ther 1998; 36:216-21.
  16. Jermendy G. For Benfotiamine Trial: Use of benfotiamine for treating diabetic polyneuropathy (Hungarian multicenter trial). Hung Arch Int Med 1996;4:223-26.
  17. Hammes HP, Du X, Edelstein D et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294-99.
  18. Bitsch R, Wolf M, Möller J, et al. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamine derivative. Ann Nutr Metab 1991;35:292-96.
  19. Thornalley PJ, Babaei-Jadidi R, Al Ali H et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007;50:2164-70.
  20. Strake H, Lindenmann A, Federlin KA. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 1996;104:311-16.
  21. Marchetti V, Menghini R, Rizza S, et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 2006;55:2231-37.
  22. Avena R, Arora S, Carmody BJ, et al. Thiamine (vitamin B1) protects against glucose- and insulin-medicated proliferation of human infragenicular arterial smooth muscle cells. Ann Vasc Surg 2000;14(1):37-43.
  23. Beltramo E, Berrone E, Buttiglieri S, Porta M. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev 2004;20:330-6.
  24. Haupt E, Ledermann H, Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy - a three-week randomized controlled pilot-study (BEDIP study). Int J Clin Pharmacol Ther 2005;43:71-7.
  25. Stracke H, Gaus W, Achenbach U, Federlin K, et al. Benfotiamine in Diabetic Polyneuropathy (BENDIP): Results of a randomised, double-blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008;116:600-5.
  26. Simeonov S, Pavlova M, Mitkov M, et al. Therapeutic efficacy of "Milgamma" in patients with painful diabetic neuropathy. Folia Med (Plovdiv) 1997;39(4):5-10.
  27. Solomon LR. Disorders of cobalamin (vitamin B12) metabolism: emerging concept in patophysiology, diagnosis and treatment. Blood Rev 2007;21:113-30.
  28. Rabbani N, Shahzad Alam S, Riaz, et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a pilot randomized, double-blind placebo-controlled study. Diabetologia 2009;52:208-12.
  29. Stirban A, Negrean M, Stratmann B, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006;29(9):2064-71.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2012

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах